Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS	4	AUG 11	STN AnaVist workshops to be held in North America
NEWS	5	AUG 30	CA/CAplus -Increased access to 19th century research documents
NEWS	6	AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS	7	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	8	SEP 22	MATHDI to be removed from STN

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:07:03 ON 26 SEP 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:07:11 ON 26 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file

provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2005 HIGHEST RN 863878-84-6
DICTIONARY FILE UPDATES: 25 SEP 2005 HIGHEST RN 863878-84-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10743287.str



chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 22 23 25 26 27 28
chain bonds :
1-2 1-16 1-18 2-3 2-25 2-26 3-4 4-5 5-6 6-7 7-8 8-9 8-20 9-10 10-11 11-12 12-13 13-14 14-15 14-27 14-28 15-17 15-19 18-23 19-22
exact/norm bonds :
1-16 1-18 8-20 15-17 15-19 18-23 19-22
exact bonds :
1-2 2-3 2-25 2-26 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14 14-15 14-27 14-28

G1:H,Ak

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 22:CLASS 23:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS

```
L1      STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 17:07:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      581 TO ITERATE

100.0% PROCESSED      581 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        10174 TO    13066
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 17:07:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    11481 TO ITERATE

100.0% PROCESSED    11481 ITERATIONS                                  2 ANSWERS
SEARCH TIME: 00.00.01

L3            2 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   161.33     161.54

FILE 'CAPLUS' ENTERED AT 17:07:41 ON 26 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 26 Sep 2005  VOL 143 ISS 14
FILE LAST UPDATED: 25 Sep 2005  (20050925/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l3
L4            2 L3
```

=> d l4 ibib hitstr abs 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:648491 CAPLUS
DOCUMENT NUMBER: 141:190505
TITLE: Preparation of hydroxyl compounds for cholesterol management and related uses
INVENTOR(S): Dasseux, Jean-Louis Henri; Oniciu, Daniela Carmen
PATENT ASSIGNEE(S): Esperion Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 348 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004067489	A2	20040812	WO 2003-US41411	20031223
WO 2004067489	A3	20041125		
WO 2004067489	C1	20050217		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004209847	A1	20041021	US 2003-743287	20031223
US 2004214887	A1	20041028	US 2003-743109	20031223
US 2005043278	A1	20050224	US 2003-743470	20031223
PRIORITY APPLN. INFO.:			US 2003-441795P P	20030123
OTHER SOURCE(S):		MARPAT 141:190505		

IT **738606-46-7P**, 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anticholesteremic agent; preparation of hydroxyalkanes for cholesterol management and related uses)
RN 738606-46-7 CAPLUS
CN Pentadecanedioic acid, 8-hydroxy-2,2,14,14-tetramethyl- (9CI) (CA INDEX NAME)



IT **738606-64-9**, 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid diethyl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hydroxyalkanes for cholesterol management and related uses)
RN 738606-64-9 CAPLUS

CN Pentadecanedioic acid, 8-hydroxy-2,2,14,14-tetramethyl-, diethyl ester (9CI) (CA INDEX NAME)



GI



I



II

AB Title hydroxyalkanes I [wherein m = 0-5; n = 3-7; X = (CH2)p or CH2; p = 0-4; R1, R2, R11, R12 = independently H, alkyl, alkenyl, alkynyl, Ph, PhCH2, wherein R1, R2, R11, and R12 are not simultaneously H; Y1, Y2 = independently alkyl, OH, CO2H, CO2R3, SO3H, (un)substituted heterocyclyl, (di)phosphate and triphosphate esters, etc.; R3 = (un)substituted alkyl, alkenyl, alkynyl, Ph, PhCH2; and pharmaceutically acceptable salts, hydrates, solvates, or mixts. thereof] were prepared for cholesterol management. Thus, reduction of 7-oxo-2,2,12,12-tetramethyltridecanedioic acid di-Et ester with Na(BH4) in MeOH gave 7-hydroxy-2,2,12,12-tetramethyltridecanedioic acid di-Et ester (92%), which was saponified with KOH in EtOH to afford the diacid II (95%). The latter inhibited lipid synthesis in primary rat hepatocytes with IC50 of 3.4 μM. In addition, the present invention relates to I, compns. comprising I, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compds. and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient (no data). In certain embodiments, I, compns. comprising I, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:518921 CAPLUS
DOCUMENT NUMBER: 141:236191
TITLE: Effects of a novel dual lipid synthesis inhibitor and

its potential utility in treating dyslipidemia and metabolic syndrome

AUTHOR(S): Cramer, Clay T.; Goetz, Brian; Hopson, Krista L. M.; Fici, Gregory J.; Ackermann, Rose M.; Brown, Stephen C.; Bisgaier, Charles L.; Rajeswaran, W. G.; Oniciu, Daniela C.; Pape, Michael E.

CORPORATE SOURCE: Esperion Therapeutics, Inc., Ann Arbor, MI, 48108, USA

SOURCE: Journal of Lipid Research (2004), 45(7), 1289-1301
CODEN: JLPRAW; ISSN: 0022-2275

PUBLISHER: American Society for Biochemistry and Molecular Biology, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

IT **738606-46-7**, ESP 55016
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effects of lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome)

RN 738606-46-7 CAPLUS

CN Pentadecanedioic acid, 8-hydroxy-2,2,14,14-tetramethyl- (9CI) (CA INDEX NAME)



AB We have identified a novel ω-hydroxy-alkane dicarboxylic acid, ESP 55016, that favorably alters serum lipid variables in obese female Zucker (fa/fa) rats. ESP 55016 reduced serum non-HDL-cholesterol (non-HDL-C), triglyceride, and nonesterified fatty acid levels while increasing serum HDL-C and β-hydroxybutyrate levels in a dose-dependent manner. ESP 55016 reduced fasting serum insulin and glucose levels while also suppressing weight gain. In primary rat hepatocytes, ESP 55016 increased the oxidation of [14C]palmitate in a dose- and carnitine palmitoyl transferase-I (CPT-I)-dependent manner. Furthermore, in primary rat hepatocytes and in vivo, ESP 55016 inhibited fatty acid and sterol synthesis. The "dual inhibitor" activity of ESP 55016 was unlikely attributable to the activation of the AMP-activated protein kinase (AMPK) pathway because AMPK and acetyl-CoA carboxylase (ACC) phosphorylation states as well as ACC activity were not altered by ESP 55016. Further studies indicated the conversion of ESP 55016 to a CoA derivative in vivo. ESP 55016-CoA markedly inhibited the activity of partially purified ACC. The activity of partially purified HMG-CoA reductase was not altered by the xenobiotic-CoA. These data suggest that ESP 55016-CoA favorably alters lipid metabolism in a model of diabetic dyslipidemia in part by initially inhibiting fatty acid and sterol synthesis plus enhancing the oxidation of fatty acids through the ACC/malonyl-CoA/CPT-I regulatory axis.

REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.23	172.77

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.46	-1.46

FILE 'REGISTRY' ENTERED AT 17:09:40 ON 26 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2005 HIGHEST RN 863878-84-6
DICTIONARY FILE UPDATES: 25 SEP 2005 HIGHEST RN 863878-84-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\107432871.str



chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 22 23
chain bonds :
1-2 1-16 1-18 2-3 3-4 4-5 5-6 6-7 7-8 8-9 8-20 9-10 10-11 11-12 12-13 13-14 14-15 15-17 15-19 18-23 19-22
exact/norm bonds :
1-16 1-18 8-20 15-17 15-19 18-23 19-22
exact bonds :

1-2 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14 14-15

G1:H,Ak

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 20:CLASS 22:CLASS 23:CLASS

L5 STRUCTURE UPLOADED

=> s l5
SAMPLE SEARCH INITIATED 17:09:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 12887 TO ITERATE

15.5% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 250940 TO 264540
PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L5

=> s l5 ful
FULL SEARCH INITIATED 17:10:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 254675 TO ITERATE

98.2% PROCESSED 250033 ITERATIONS 5 ANSWERS

100.0% PROCESSED 254675 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.18

L7 6 SEA SSS FUL L5

=> d l7 ibib hitstr abs 1-6
'IBIB' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'HITSTR' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'ABS' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used

SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties
EPROP - Table of experimental properties
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):end

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.76	334.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.46

FILE 'CAPLUS' ENTERED AT 17:10:59 ON 26 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 26 Sep 2005 VOL 143 ISS 14
FILE LAST UPDATED: 25 Sep 2005 (20050925/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 17:07:03 ON 26 SEP 2005)

FILE 'REGISTRY' ENTERED AT 17:07:11 ON 26 SEP 2005
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 2 S L1 FUL

FILE 'CAPLUS' ENTERED AT 17:07:41 ON 26 SEP 2005
L4 2 S L3

FILE 'REGISTRY' ENTERED AT 17:09:40 ON 26 SEP 2005
L5 STRUCTURE UPLOADED
L6 0 S L5
L7 6 S L5 FUL

FILE 'CAPLUS' ENTERED AT 17:10:59 ON 26 SEP 2005

=> s l7
L8 5 L7

=> d l8 ibib hitstr abs 1-5

L8 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:411319 CAPLUS
DOCUMENT NUMBER: 143:97083
TITLE: Organozinc alkoxide-promoted aldol-Tishchenko reaction of aliphatic aldehydes: an expedient entry to prepare the α-methylene ketones
AUTHOR(S): Hon, Yung-Son; Chang, Chun-Ping
CORPORATE SOURCE: Department of Chemistry and Biochemistry, National Chung Cheng University, Taipei, 621, Peop. Rep. China
SOURCE: Tetrahedron (2005), 61(22), 5267-5275
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **856895-80-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of α-methylene ketones via organozinc alkoxide-promoted aldol-Tishchenko reaction of aliphatic aldehydes and subsequent oxidation
and

elimination)
RN 856895-80-2 CAPLUS
CN Pentadecanedioic acid, 8-hydroxy-7-[[(8-methoxy-1,8-dioxooctyl)oxy]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



AB I-PrOZnEt is an excellent reagent to promote the aldol-Tishchenko reaction of the aliphatic aldehydes tethered with other labile functional groups. The 1,3-diol monoesters were formed as the major products, which could be converted to α-methylene ketones in two steps in good yields. E.g., reaction of BnCH2CHO in presence of i-PrOZnEt gave BnCH2CH(OH)CHBnCH2O2CCH2Bn as the major product and BnCH2CH(O2CCH2Bn)CHBnCH2OH as the minor product. Oxidation of the mixture of products by PCC gave BnCH2COCHCH2O2CCH2Bn as the major product. Treatment of this ketone by DBU led to the α-methylene ketone BnCH2COCBn:CH2.
REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:648491 CAPLUS
DOCUMENT NUMBER: 141:190505
TITLE: Preparation of hydroxyl compounds for cholesterol management and related uses
INVENTOR(S): Dasseux, Jean-Louis Henri; Oniciu, Daniela Carmen
PATENT ASSIGNEE(S): Esperion Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 348 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004067489	A2	20040812	WO 2003-US41411	20031223
WO 2004067489	A3	20041125		
WO 2004067489	C1	20050217		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004209847	A1	20041021	US 2003-743287	20031223
US 2004214887	A1	20041028	US 2003-743109	20031223
US 2005043278	A1	20050224	US 2003-743470	20031223
PRIORITY APPLN. INFO.:			US 2003-441795P P	20030123

OTHER SOURCE(S): MARPAT 141:190505

IT **738606-46-7P**, 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
738606-61-6P, 8-Hydroxy-2,2,12,12-tetramethylpentadecanedioic acid diethyl ester
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anticholesteremic agent; preparation of hydroxyalkanes for cholesterol management and related uses)

RN 738606-46-7 CAPLUS

CN Pentadecanedioic acid, 8-hydroxy-2,2,14,14-tetramethyl- (9CI) (CA INDEX NAME)



RN 738606-61-6 CAPLUS

CN Pentadecanedioic acid, 8-hydroxy-2,2,12,12-tetramethyl-, diethyl ester (9CI) (CA INDEX NAME)



IT **738606-64-9**, 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid diethyl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hydroxyalkanes for cholesterol management and related uses)

RN 738606-64-9 CAPLUS

CN Pentadecanedioic acid, 8-hydroxy-2,2,14,14-tetramethyl-, diethyl ester (9CI) (CA INDEX NAME)



GI



I



II

AB Title hydroxyalkanes I [wherein m = 0-5; n = 3-7; X = (CH2)p or CH2; p = 0-4; R1, R2, R11, R12 = independently H, alkyl, alkenyl, alkynyl, Ph, PhCH2, wherein R1, R2, R11, and R12 are not simultaneously H; Y1, Y2 = independently alkyl, OH, CO2H, CO2R3, SO3H, (un)substituted heterocyclyl, (di)phosphate and triphosphate esters, etc.; R3 = (un)substituted alkyl, alkenyl, alkynyl, Ph, PhCH2; and pharmaceutically acceptable salts, hydrates, solvates, or mixts. thereof] were prepared for cholesterol management. Thus, reduction of 7-oxo-2,2,12,12-tetramethyltridecanedioic acid di-Et ester with Na(BH4) in MeOH gave 7-hydroxy-2,2,12,12-tetramethyltridecanedioic acid di-Et ester (92%), which was saponified with KOH in EtOH to afford the diacid II (95%). The latter inhibited lipid synthesis in primary rat hepatocytes with IC50 of 3.4 μM. In addition, the present invention relates to I, compns. comprising I, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compds. and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient (no data). In certain embodiments, I, compns. comprising I, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	2004:518921 CAPLUS
DOCUMENT NUMBER:	141:236191
TITLE:	Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome
AUTHOR(S):	Cramer, Clay T.; Goetz, Brian; Hopson, Krista L. M.; Fici, Gregory J.; Ackermann, Rose M.; Brown, Stephen C.; Bisgaier, Charles L.; Rajeswaran, W. G.; Oniciu, Daniela C.; Pape, Michael E.
CORPORATE SOURCE:	Esperion Therapeutics, Inc., Ann Arbor, MI, 48108, USA
SOURCE:	Journal of Lipid Research (2004), 45(7), 1289-1301 CODEN: JLPRAW; ISSN: 0022-2275
PUBLISHER:	American Society for Biochemistry and Molecular Biology, Inc.
DOCUMENT TYPE:	Journal
LANGUAGE:	English

IT **738606-46-7**, ESP 55016
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effects of lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome)
RN 738606-46-7 CAPLUS
CN Pentadecanedioic acid, 8-hydroxy-2,2,14,14-tetramethyl- (9CI) (CA INDEX NAME)



AB We have identified a novel ω-hydroxy-alkane dicarboxylic acid, ESP 55016, that favorably alters serum lipid variables in obese female Zucker (fa/fa) rats. ESP 55016 reduced serum non-HDL-cholesterol (non-HDL-C), triglyceride, and nonesterified fatty acid levels while increasing serum HDL-C and β-hydroxybutyrate levels in a dose-dependent manner. ESP 55016 reduced fasting serum insulin and glucose levels while also suppressing weight gain. In primary rat hepatocytes, ESP 55016 increased the oxidation of [14C]palmitate in a dose- and carnitine palmitoyl transferase-I (CPT-I)-dependent manner. Furthermore, in primary rat hepatocytes and in vivo, ESP 55016 inhibited fatty acid and sterol synthesis. The "dual inhibitor" activity of ESP 55016 was unlikely attributable to the activation of the AMP-activated protein kinase (AMPK) pathway because AMPK and acetyl-CoA carboxylase (ACC) phosphorylation states as well as ACC activity were not altered by ESP 55016. Further studies indicated the conversion of ESP 55016 to a CoA derivative in vivo. ESP 55016-CoA markedly inhibited the activity of partially purified ACC. The activity of partially purified HMG-CoA reductase was not altered by the xenobiotic-CoA. These data suggest that ESP 55016-CoA favorably alters lipid metabolism in a model of diabetic dyslipidemia in part by initially inhibiting fatty acid and sterol synthesis plus enhancing the oxidation of fatty acids through the ACC/malonyl-CoA/CPT-I regulatory axis.
REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1987:196107 CAPLUS
DOCUMENT NUMBER: 106:196107
TITLE: Enamine condensation on derivatives of aleuritic acid and synthesis of (Z)-9-tricosene (muscalure), its (E)-isomer, and (E)-13-heptacosene
AUTHOR(S): Subramanian, G. B. V.; Mehrotra, Alka; Mehrotra, Kalpana
CORPORATE SOURCE: Dep. Chem., Univ. Delhi, Delhi, 110007, India
SOURCE: Tetrahedron (1986), 42(14), 3967-72
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 106:196107
IT **93416-11-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate in synthesis of heptacosene)
RN 93416-11-6 CAPLUS
CN Pentadecanedioic acid, 7,8-dihydroxy-, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



AB Enamine condensation on (9RS,10RS)-9,10,16-triacetoxyhexadecanoyl chloride as well as (7RS,8RS)-7,8-diacetoxy-1,15-pentadecadioyl chloride using 1-morpholino-1-cyclohexene led to chain elongated products with 22 and 27 carbon atoms resp. The 22 carbon product was converted into (Z)-9-tricosene and its E-isomer, while the 27 carbon product led to a synthesis of (E)-13-heptacosene.

L8 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1985:5642 CAPLUS
DOCUMENT NUMBER: 102:5642
TITLE: Preparation of some hydroxypentadecane derivatives from threo-aleuritic acid
AUTHOR(S): Subramanian, G. B. V.; Mehrotra, Kalpana
CORPORATE SOURCE: Dep. Chem., Univ. Delhi, Delhi, 110 007, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1984), 23B(4), 384-5
CODEN: IJSBDB; ISSN: 0376-4699
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **93416-11-6P 93416-12-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 93416-11-6 CAPLUS
CN Pentadecanedioic acid, 7,8-dihydroxy-, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 93416-12-7 CAPLUS
CN Pentadecanedioic acid, 7,8-dihydroxy-, dimethyl ester, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



AB The triacetate of threo-aleuritic acid (9,10,16-trihydroxypalmitic acid), on treatment with Pb(OAc)4 and iodine in the presence of light followed by deacetylation gave R(CH2)5CH(OH)CH(OH)(CH2)6R1 (I; R = CH2OH, R1 = CH2I) (II). Acetoxylation and hydrolysis of II gave I (R = R1 = CH2OH). II was reduced to give I (R = CH2OH, R1 = Me). Oxidation of protected I (R = CH2OH; R1 = CH2I, CH2OH, Me) gave the acids I (R = CO2H; R1 = CH2I, CO2H, Me), which were methylated to the resp. esters.

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	27.85	362.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.65	-5.11

FILE 'REGISTRY' ENTERED AT 17:15:17 ON 26 SEP 2005

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2005 HIGHEST RN 863878-84-6
DICTIONARY FILE UPDATES: 25 SEP 2005 HIGHEST RN 863878-84-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from  *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005. A new display format, IDERL, is now      *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\107432872.str



chain nodes :
1 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 22 23
ring nodes :
2 25 26
chain bonds :
1-2 1-16 1-18 2-3 3-4 4-5 5-6 6-7 7-8 8-9 8-20 9-10 10-11 11-12 12-13
13-14 14-15 15-17 15-19 18-23 19-22
ring bonds :
2-25 2-26 25-26
exact/norm bonds :
1-16 1-18 2-25 2-26 8-20 15-17 15-19 18-23 19-22 25-26
exact bonds :
1-2 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14 14-15

G1:H,Ak

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 20:CLASS 22:CLASS 23:CLASS 25:Atom 26:Atom

L9 STRUCTURE UPLOADED

=> s l9
SAMPLE SEARCH INITIATED 17:15:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 449 TO ITERATE

100.0% PROCESSED 449 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7709 TO 10251
PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM L9

=> s l9 ful
FULL SEARCH INITIATED 17:15:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 8839 TO ITERATE

100.0% PROCESSED 8839 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L11 1 SEA SSS FUL L9

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.33	523.71

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.11

FILE 'CAPLUS' ENTERED AT 17:15:45 ON 26 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 26 Sep 2005 VOL 143 ISS 14
FILE LAST UPDATED: 25 Sep 2005 (20050925/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l11
L12 1 L11

=> d l12 ibib hitstr abs

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:648491 CAPLUS
DOCUMENT NUMBER: 141:190505
TITLE: Preparation of hydroxyl compounds for cholesterol management and related uses
INVENTOR(S): Dasseux, Jean-Louis Henri; Oniciu, Daniela Carmen
PATENT ASSIGNEE(S): Esperion Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 348 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004067489	A2	20040812	WO 2003-US41411	20031223
WO 2004067489	A3	20041125		
WO 2004067489	C1	20050217		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004209847	A1	20041021	US 2003-743287	20031223
US 2004214887	A1	20041028	US 2003-743109	20031223
US 2005043278	A1	20050224	US 2003-743470	20031223

PRIORITY APPLN. INFO.: US 2003-441795P P 20030123
OTHER SOURCE(S): MARPAT 141:190505

IT **738607-05-1P**, 13-(1-Carboxycyclopropyl)-8-hydroxy-2,2-dimethyltridecanoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anticholesteremic agent; preparation of hydroxyalkanes for cholesterol management and related uses)

RN 738607-05-1 CAPLUS
CN Cyclopropanetridecanoic acid, 1-carboxy-η-hydroxy-α,α-dimethyl- (9CI) (CA INDEX NAME)



GI



AB Title hydroxyalkanes I [wherein m = 0-5; n = 3-7; X = (CH2)p or CH2; p = 0-4; R1, R2, R11, R12 = independently H, alkyl, alkenyl, alkynyl, Ph, PhCH2, wherein R1, R2, R11, and R12 are not simultaneously H; Y1, Y2 = independently alkyl, OH, CO2H, CO2R3, SO3H, (un)substituted heterocyclyl, (di)phosphate and triphosphate esters, etc.; R3 = (un)substituted alkyl, alkenyl, alkynyl, Ph, PhCH2; and pharmaceutically acceptable salts, hydrates, solvates, or mixts. thereof] were prepared for cholesterol management. Thus, reduction of 7-oxo-2,2,12,12-tetramethyltridecanedioic acid di-Et ester with Na(BH4) in MeOH gave 7-hydroxy-2,2,12,12-

tetramethyltridecanedioic acid di-Et ester (92%), which was saponified with KOH in EtOH to afford the diacid II (95%). The latter inhibited lipid synthesis in primary rat hepatocytes with IC50 of 3.4 μM. In addition, the present invention relates to I, compns. comprising I, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compds. and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient (no data). In certain embodiments, I, compns. comprising I, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     6.29     530.00

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -0.73      -5.84

FILE 'REGISTRY' ENTERED AT 17:17:44 ON 26 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   25 SEP 2005  HIGHEST RN 863878-84-6
DICTIONARY FILE UPDATES:  25 SEP 2005  HIGHEST RN 863878-84-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
```

information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\107432973.str



chain nodes :
1 3 4 5 6 7 8 9 10 11 12 13 15 16 17 18 19 20 22 23
ring nodes :
2 14 25 26 27 28
chain bonds :
1-2 1-16 1-18 2-3 3-4 4-5 5-6 6-7 7-8 8-9 8-20 9-10 10-11 11-12 12-13
13-14 14-15 15-17 15-19 18-23 19-22
ring bonds :
2-25 2-26 14-27 14-28 25-26 27-28
exact/norm bonds :
1-16 1-18 2-25 2-26 8-20 14-27 14-28 15-17 15-19 18-23 19-22 25-26
27-28
exact bonds :
1-2 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14 14-15

G1:H,Ak

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 20:CLASS 22:CLASS 23:CLASS 25:Atom 26:Atom 27:Atom
28:Atom

L13 STRUCTURE UPLOADED

=> s l13
SAMPLE SEARCH INITIATED 17:18:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 230 TO ITERATE

100.0% PROCESSED 230 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3691 TO 5509
PROJECTED ANSWERS: 0 TO 0

L14 0 SEA SSS SAM L13

```
=> s l13 ful
FULL SEARCH INITIATED 17:18:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     4730 TO ITERATE

100.0% PROCESSED     4730 ITERATIONS                                 2 ANSWERS
SEARCH TIME: 00.00.01

L15            2 SEA SSS FUL L13

=> file caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     161.33     691.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)            SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -5.84

FILE 'CAPLUS' ENTERED AT 17:18:14 ON 26 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 26 Sep 2005  VOL 143 ISS 14
FILE LAST UPDATED: 25 Sep 2005  (20050925/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l15
L16            1 L15

=> file reg
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       2.70     694.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)            SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -5.84

FILE 'REGISTRY' ENTERED AT 17:21:45 ON 26 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
```

provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2005 HIGHEST RN 863878-84-6
DICTIONARY FILE UPDATES: 25 SEP 2005 HIGHEST RN 863878-84-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\107432974.str



chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 17 18 19 20 21
chain bonds :
1-2 1-18 1-19 2-3 3-4 4-5 5-6 6-7 7-8 7-20 8-9 9-10 10-11 11-12 12-13 13-14 13-15 15-17 19-21
exact/norm bonds :
1-18 1-19 7-20 13-14 13-15 15-17 19-21
exact bonds :
1-2 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-13

G1:H,Ak

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS

```
L17     STRUCTURE UPLOADED

=> s l17
SAMPLE SEARCH INITIATED 17:22:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    12887 TO ITERATE

 15.5% PROCESSED     2000 ITERATIONS                                 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       250940 TO   264540
PROJECTED ANSWERS:               0 TO        0

L18           0 SEA SSS SAM L17

=> s l17 ful
FULL SEARCH INITIATED 17:22:09 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   254675 TO ITERATE

 98.1% PROCESSED   249891 ITERATIONS                                 5 ANSWERS

100.0% PROCESSED   254675 ITERATIONS                                 6 ANSWERS
SEARCH TIME: 00.00.19

L19           6 SEA SSS FUL L17

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                   161.33     855.36

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                     0.00      -5.84

FILE 'CAPLUS' ENTERED AT 17:22:34 ON 26 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 26 Sep 2005  VOL 143 ISS 14
FILE LAST UPDATED: 25 Sep 2005  (20050925/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l19
L20           3 L19

=> d l20 ibib hitstr abs 1-3

L20  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2004:648491  CAPLUS
DOCUMENT NUMBER:          141:190505
TITLE:                    Preparation of hydroxyl compounds for cholesterol
                          management and related uses
INVENTOR(S):              Dasseux, Jean-Louis Henri; Oniciu, Daniela Carmen
PATENT ASSIGNEE(S):       Esperion Therapeutics, Inc., USA
SOURCE:                   PCT Int. Appl., 348 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     --------------       ----   --------    --------------------     --------
     WO 2004067489         A2    20040812    WO 2003-US41411          20031223
     WO 2004067489         A3    20041125
     WO 2004067489         C1    20050217
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
            GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
            LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
            OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
            TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
            ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
            TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2004209847         A1    20041021    US 2003-743287           20031223
     US 2004214887         A1    20041028    US 2003-743109           20031223
     US 2005043278         A1    20050224    US 2003-743470           20031223
PRIORITY APPLN. INFO.:                       US 2003-441795P     P    20030123
OTHER SOURCE(S):          MARPAT 141:190505
IT   738606-33-2P, 7-Hydroxy-2,2,12,12-tetramethyltridecanedioic acid
     diethyl ester
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (anticholesteremic agent; preparation of hydroxyalkanes for cholesterol
        management and related uses)
RN   738606-33-2  CAPLUS
CN   Tridecanedioic acid, 7-hydroxy-2,2,12,12-tetramethyl-, diethyl ester (9CI)
       (CA INDEX NAME)
```



IT **738606-34-3P**, 7-Hydroxy-2,2,12,12-tetramethyltridecanedioic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anticholesteremic agent; preparation of hydroxyalkanes for cholesterol management and related uses)

RN 738606-34-3 CAPLUS

CN Tridecanedioic acid, 7-hydroxy-2,2,12,12-tetramethyl- (9CI) (CA INDEX NAME)



GI



I

II

AB Title hydroxyalkanes I [wherein m = 0-5; n = 3-7; X = (CH2)p or CH2; p = 0-4; R1, R2, R11, R12 = independently H, alkyl, alkenyl, alkynyl, Ph, PhCH2, wherein R1, R2, R11, and R12 are not simultaneously H; Y1, Y2 = independently alkyl, OH, CO2H, CO2R3, SO3H, (un)substituted heterocyclyl, (di)phosphate and triphosphate esters, etc.; R3 = (un)substituted alkyl, alkenyl, alkynyl, Ph, PhCH2; and pharmaceutically acceptable salts, hydrates, solvates, or mixts. thereof] were prepared for cholesterol management. Thus, reduction of 7-oxo-2,2,12,12-tetramethyltridecanedioic acid di-Et ester with Na(BH4) in MeOH gave 7-hydroxy-2,2,12,12-tetramethyltridecanedioic acid di-Et ester (92%), which was saponified with KOH in EtOH to afford the diacid II (95%). The latter inhibited lipid synthesis in primary rat hepatocytes with IC50 of 3.4 μM. In addition, the present invention relates to I, compns. comprising I, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia,

hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compds. and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient (no data). In certain embodiments, I, compns. comprising I, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

L20 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1987:496416 CAPLUS
DOCUMENT NUMBER: 107:96416
TITLE: A synthesis of polyoxygenated polycyclic aromatic compounds via polyketides
AUTHOR(S): Yamaguchi, Masahiko; Hasebe, Koichi; Shibato, Keisuke; Nakashima, Hisataka; Minami, Toru
CORPORATE SOURCE: Dep. Ind. Chem., Kyushu Inst. Technol., Japan
SOURCE: Tennen Yuki Kagobutsu Toronkai Koen Yoshishu (1986), 28th, 627-34
CODEN: TYKYDS
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
IT **109873-12-3P 109873-25-8P 109873-26-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and intramol. cyclization of)
RN 109873-12-3 CAPLUS
CN Tridecanedioic acid, 7-hydroxy-3,5,9,11-tetraoxo-, dimethyl ester (9CI) (CA INDEX NAME)



RN 109873-25-8 CAPLUS
CN Tridecanedioic acid, 7-ethyl-7-hydroxy-3,5,9,11-tetraoxo-, dimethyl ester (9CI) (CA INDEX NAME)



RN 109873-26-9 CAPLUS
CN Tridecanedioic acid, 7-hydroxy-3,5,9,11-tetraoxo-7-(3-phenylpropyl)-, dimethyl ester (9CI) (CA INDEX NAME)



GI



I



II



III



IV

AB A biomimetic synthesis of polyoxygenated polycyclic aromatic compds. via polyketides was examined Several polyoxoalkanedioates were generated from dicarboxylic acid derivs. and Me acetoacetate dianion. The intramol. condensation of the resulting polyketo esters gave phenolic compds., e.g., indanone I. Ca(OAc)2 was one of the best catalysts. Treatment of aromatic glutarates with the dianion followed by Ca(OAc)2 afforded polyhydroxy derivs. of anthracene and naphthacene related to the natural products. The arenes were oxidized to the corresponding quinones with O2 under basic conditions. The quinones also are aromatic glutarates, and were subjected to further extension of the ring system. Thus, benzanthracene II, prepared from naphthalene III (R = CO2Me, R1 = CH2CO2Me) via polyketide III [R = (COCH2)2CO2Me, R1 = CH2(COCH2)2CO2Me], as outlined above, was converted to dibenzanthracene IV.

L20 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1941:22768 CAPLUS
DOCUMENT NUMBER: 35:22768
ORIGINAL REFERENCE NO.: 35:3608a-g
TITLE: Wound hormones of plants. V. The synthesis of some analogs of traumatic acid
AUTHOR(S): English, James, Jr.
SOURCE: Journal of the American Chemical Society (1941), 63, 941-3
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
IT **855245-29-3**, Brassylic acid, ζ-hydroxy-
(preparation of)
RN 855245-29-3 CAPLUS
CN Brassylic acid, ζ-hydroxy- (4CI) (CA INDEX NAME)



AB cf. C. A. 34, 1052.9. The following unsatd. dibasic acids were prepared to test their activity as plant wound hormones. Et sebacate chloride, from the acid ester and SOCl2 in 82% yield, b1 129-30°. The aldehyde esters were prepared from the chlorides by Rosemund's method. Δ1-Unsatd. acids were prepared by adding the desired ester to an equivalent amount of CH2(CO2H)2 in 2-3 times its weight of C5H5N, allowing the mixture to stand 3-5 days, heating on the steam bath for 3 h., acidifying and extracting with ether; the crude mixture of acid esters is hydrolyzed with 2 N EtOH-NaOH, the acids precipitated with dilute HCl and purified by passing the ether solution through a column packed with an intimate mixture of C and supercel, with final crystallization from dilute EtOH or AcOH; the yields were 30-50%. The Δ2-unsatd. acids were prepared as above but with the use of PhNMe2 in place of C5H5N, with sufficient dry MeOH to give a homogeneous reaction mixture; the Δ2-acids were more soluble in ether and less strongly adsorbed on C than the corresponding Δ1-acids. I was also prepared by the method of Bergmann (C. A. 35, 79.7) by using pure azelaic semialdehyde. The following dicarboxylic acids were prepared by these methods: Δ1-nonene-1,9- (I), m. 103°; Δ2-isomer, m. 90°; Δ1-decene-1,10-, m. 165°; Δ2-isomer, m. 109°; Δ1-tridecene-1,13-, m. 108.5°; Δ2-isomer, m. 104°. Heating 40 g. Et α,α'-dibromosebacate and 30 g. PhNMe2 at 180° for 16 h. gives a crude yield of 10 g. of 1,7-octadiene-1,8-dicarboxylic acid, m. 236-9° (decomposition); catalytic reduction of 2 g. with PtO2 (addition of 1 mol. of H) gives 0.6 g. of 1-octene-1,8-dicarboxylic acid, m. 173°. Alkylation of CO(CH2CO2H)2 with PrCHICO2Et according to von Pechman and Sidgwick (Ber. 37, 3816(1904)) (refluxing about 8 h. for each stage), hydrolysis of the material boiling above 150° at 1 mm. by refluxing with 4 times its weight of concentrated HCl for 6-8 h. and crystallization from H2O or dilute EtOH give 52% of 6-undecanone-1,11-dicarboxylic acid (II), m. 114°; 5-nonanone-1,9-dicarboxylic acid, prepared with EtCHICO2H, m. 111°. Reduction of II with PtO2 and a pressure of 30-40 lb. H in equal vols. of ether and alc. for 2-6 days gives a nearly quant. yield of 6-undecanol-1,11-dicarboxylic acid (III), m. 102-3°; 5-nonanol-1,9-dicarboxylic acid, m. 95°. Heating III with a slight excess of PI3 on the steam bath for 3 h. and refluxing the crude iodo acid with 25% EtOH-KOH for 3 h. give 5-undecene-1,11-dicarboxylic acid, m. 72°; pure 4-nonene-1,9-dicarboxylic acid could not be prepared by this method. All these acids show wound-hormone activity when tested in the presence of the standard co-factor mixture; in all cases the unsatd. acids are more active than the corresponding saturated compds.

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.17	871.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.19	-8.03

FILE 'REGISTRY' ENTERED AT 17:24:19 ON 26 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2005 HIGHEST RN 863878-84-6
DICTIONARY FILE UPDATES: 25 SEP 2005 HIGHEST RN 863878-84-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\107432975.str



chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 17 18 19 20 21 23 24
chain bonds :
1-2 1-18 1-19 2-3 3-4 4-5 5-6 6-7 7-8 7-20 8-9 9-10 10-11 11-12 12-13 12-23 12-24 13-14 13-15 15-17 19-21
exact/norm bonds :
1-18 1-19 7-20 13-14 13-15 15-17 19-21
exact bonds :
1-2 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-13 12-23 12-24

10/4743,297

G1:H,Ak

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 23:CLASS 24:CLASS

L21 STRUCTURE UPLOADED

=> s l21
SAMPLE SEARCH INITIATED 17:24:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 776 TO ITERATE

100.0% PROCESSED 776 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 13849 TO 17191
PROJECTED ANSWERS: 0 TO 0

L22 0 SEA SSS SAM L21

=> s l21 ful
FULL SEARCH INITIATED 17:24:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 15418 TO ITERATE

100.0% PROCESSED 15418 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L23 2 SEA SSS FUL L21

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.33	1032.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-8.03

FILE 'CAPLUS' ENTERED AT 17:24:57 ON 26 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 26 Sep 2005 VOL 143 ISS 14
FILE LAST UPDATED: 25 Sep 2005 (20050925/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l23
L24 1 L23

=> d l24 ibib hitstr abs

L24 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:648491 CAPLUS
DOCUMENT NUMBER: 141:190505
TITLE: Preparation of hydroxyl compounds for cholesterol management and related uses
INVENTOR(S): Dasseux, Jean-Louis Henri; Oniciu, Daniela Carmen
PATENT ASSIGNEE(S): Esperion Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 348 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004067489	A2	20040812	WO 2003-US41411	20031223
WO 2004067489	A3	20041125		
WO 2004067489	C1	20050217		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004209847	A1	20041021	US 2003-743287	20031223
US 2004214887	A1	20041028	US 2003-743109	20031223
US 2005043278	A1	20050224	US 2003-743470	20031223
PRIORITY APPLN. INFO.:			US 2003-441795P P	20030123

OTHER SOURCE(S): MARPAT 141:190505
IT **738606-33-2P**, 7-Hydroxy-2,2,12,12-tetramethyltridecanedioic acid diethyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(anticholesteremic agent; preparation of hydroxyalkanes for cholesterol management and related uses)
RN 738606-33-2 CAPLUS
CN Tridecanedioic acid, 7-hydroxy-2,2,12,12-tetramethyl-, diethyl ester (9CI) (CA INDEX NAME)



IT **738606-34-3P**, 7-Hydroxy-2,2,12,12-tetramethyltridecanedioic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anticholesteremic agent; preparation of hydroxyalkanes for cholesterol management and related uses)

RN 738606-34-3 CAPLUS

CN Tridecanedioic acid, 7-hydroxy-2,2,12,12-tetramethyl- (9CI) (CA INDEX NAME)



GI



AB Title hydroxyalkanes I [wherein m = 0-5; n = 3-7; X = (CH2)p or CH2; p = 0-4; R1, R2, R11, R12 = independently H, alkyl, alkenyl, alkynyl, Ph, PhCH2, wherein R1, R2, R11, and R12 are not simultaneously H; Y1, Y2 = independently alkyl, OH, CO2H, CO2R3, SO3H, (un)substituted heterocyclyl, (di)phosphate and triphosphate esters, etc.; R3 = (un)substituted alkyl, alkenyl, alkynyl, Ph, PhCH2; and pharmaceutically acceptable salts, hydrates, solvates, or mixts. thereof] were prepared for cholesterol management. Thus, reduction of 7-oxo-2,2,12,12-tetramethyltridecanedioic acid di-Et ester with Na(BH4) in MeOH gave 7-hydroxy-2,2,12,12-tetramethyltridecanedioic acid di-Et ester (92%), which was saponified with KOH in EtOH to afford the diacid II (95%). The latter inhibited lipid synthesis in primary rat hepatocytes with IC50 of 3.4 μM. In addition, the present invention relates to I, compns. comprising I, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia,

hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compds. and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient (no data). In certain embodiments, I, compns. comprising I, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.39	1038.25

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.73	-8.76

STN INTERNATIONAL LOGOFF AT 17:25:48 ON 26 SEP 2005